Autologous TILs are isolated from the tumor, expanded ex vivo, and reinfused as a polyclonal T‑cell product that recognizes tumor antigens via native, HLA‑restricted TCRs and eliminates tumor cells through cytotoxic effector functions (perforin/granzyme) and cytokine release, restoring antitumor immunity without genetic engineering.